EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

  • STATUS
    Recruiting
  • End date
    Jun 25, 2022
  • participants needed
    218
  • sponsor
    SynCore Biotechnology Co., Ltd.
Updated on 25 April 2021
cancer
metastatic adenocarcinoma
pancreatic adenocarcinoma
gemcitabine
tubal sterilization
adenocarcinoma
metastatic pancreatic cancer
folfirinox

Summary

The aim of this adaptive Phase 3 trial is to show a statistically significant superiority of EndoTAG-1 in combination with gemcitabine compared to gemcitabine monotherapy in patients with locally advanced/metastatic pancreatic cancer after FOLFIRINOX failure.

Details
Condition Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Locally Advanced Pancreatic Cancer, Islet Ce417ll Cancer, FOLFIRINOX, Metastatic Pancreas Cancer
Treatment Gemcitabine, EndoTAG-1
Clinical Study IdentifierNCT03126435
SponsorSynCore Biotechnology Co., Ltd.
Last Modified on25 April 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note